Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir [1]

American Journal of Transplantation

Volumn 5, Issue 7, 2005, Pages 1781-1782

  Fellay, Jacques ^a   Venetz, Jean Pierre ^a   Pascual, Manuel ^a   Aubert, John David ^a   Seydoux, Charles ^a   Meylan, Pascal R A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMOCYTE ANTIBODY; VALACICLOVIR; VALGANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; BLOOD CULTURE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; LETTER; MALE; ORGAN TRANSPLANTATION; OUTPATIENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETINITIS;

ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION;

EID: 21344457268     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.00936.x     Document Type: Letter

References (7)

1. American Society of Transplantation, Infectious Disease Community of Practice. Cytomegalovirus. Am J Transplant 2004; 4: 51-58.
2. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218-227.
3. Reusser P. Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts. Expert Opin Investig Drugs 2001; 10: 1745-1753.
4. Martin DF, Sierra-Madero J, Walmsley S et al A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346: 1119-1126.
5. Muheim C, Vogel G, Seydoux C et al Determinants of protracted cytomegalovirus infection in solid-organ transplant patients. Transplantation 2002; 74: 226-236.
6. Babel N, Gabdrakhmanova L, Juergensen JS et al Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single center experience. Transplantation 2004; 78: 283-285.
7. Mattes FM, Hainsworth EG, Hassan-Walker AF et al Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005; 191: 89-92.